Mangoceuticals, Inc. - SIC # 5993 - TOBACCO STORES AND STANDS

Ticker Exchange SIC # Website Latest Ticker
MGRX Nasdaq 5993 www.mangoceuticals.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Mangoceuticals, Inc.

Mangoceuticals shares results from field studies on MGX-0024 - May 28th, 2025 7:15 am
Mangoceuticals’ Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu - May 27th, 2025 7:00 am
Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division - Apr 25th, 2025 7:00 am
Mangoceuticals Is Reengineering the Self-Care Blueprint with Better Personal Health and Wellness Solutions - Apr 24th, 2025 6:00 am
CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape - Apr 22nd, 2025 11:55 am
Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada - Mar 25th, 2025 7:00 am
Mangoceuticals Announces the Launch of “PeachesRx” - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments - Feb 20th, 2025 5:00 am
Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution - Feb 12th, 2025 6:00 am
Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research - Feb 6th, 2025 5:00 am
Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation - Feb 3rd, 2025 6:30 am
Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent - Dec 19th, 2024 3:33 pm
Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split - Dec 4th, 2024 5:00 am
Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement - Oct 31st, 2024 6:00 am
MangoRx Announces Formation of Strategy and Alternatives Committee - Oct 22nd, 2024 6:00 am
MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly - Oct 21st, 2024 3:10 pm
Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024 - Oct 18th, 2024 6:45 am
Mangoceuticals announces 1-for-15 reverse stock split - Oct 12th, 2024 3:20 pm
MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN - Oct 11th, 2024 3:15 pm
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions - Oct 3rd, 2024 6:30 am
MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment - Oct 1st, 2024 5:30 am